Wednesday
SESSION 31: ADVANCES IN MEDICAL TREATMENTS, NEW ANTI-ATHEROGENIC DRUGS, VALUE OF RIVAROXABAN AND PREVENTING MIs IN VASCULAR SURGERY PATIENTS
Location: Grand Ballroom West, 3rd Floor
Moderators:Peter Henke, MD / Ido Weinberg, MD, MSc  
SESSION 31 SCHEDULE
6:40 AM - 6:45 AM When, Why And How To Lower High Triglyceride Levels: Value Of Vascepa To Decrease Cardiac Risk In Vascular Patients: Based On The REDUCE-IT RCT
  Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC   
Location: Grand Ballroom West, 3rd Floor
6:46 AM - 6:51 AM New Strategies On How To Avoid And Treat Periprocedural Myocardial Infarctions (MIs) In Open Endo Vascular Surgery Patients
  Presenter(s):Peter Henke, MD  
Location: Grand Ballroom West, 3rd Floor
6:52 AM - 6:57 AM DEBATE: LDL Cholesterol (LDL-C) Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful: What Does The Latest Evidence Show
  Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC PhD FACS  
Location: Grand Ballroom West, 3rd Floor
6:58 AM - 7:03 AM DEBATE: Not So: Update On LDL-C Lowering With Statins And Other Drugs Stabilizes And Shrinks Plaques And Decreases Morbid Vascular Events: Stopping Statins Increases Patients’ Risk Of MI And Death
  Presenter(s):Ron Waksman, MD  
Location: Grand Ballroom West, 3rd Floor
7:04 AM - 7:09 AM Update On LDL-C Lowering During A Lifetime: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins: Why And How Often Should LDL-C Levels Be Measured
  Presenter(s):J. David Spence, MD  
Location: Grand Ballroom West, 3rd Floor
7:10 AM - 7:15 AM LDL-C Lowering Should Be Maximized With High Dose Statins And Ezetimibe (Zetia) To Minimize Risks From Atherosclerotic Lesions: The LDL-C Level Cannot Be Too Low And Side Effects Are Minor: LDL-C Levels Must Be Monitored And Treated To A Target Level
  Presenter(s):Anne L. Abbott, MD, PhD, FRACP  
Location: Grand Ballroom West, 3rd Floor
7:16 AM - 7:21 AM New Findings From The VOYAGER PAD And COMPASS Trials With Low Dose Rivaroxaban (Xarelto From Janssen And J&J) And Aspirin: How Do These Drugs Lower Major Adverse Limb And Cardiac Event Rates After Lower Extremity Revascularization (Endo And Open) For PAD
  Presenter(s):Marianne Brodmann, MD / Sebastian E. Debus, MD, PhD  
Location: Grand Ballroom West, 3rd Floor
7:22 AM - 7:27 AM How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials
  Presenter(s):Anthony J. Comerota, MD, FACS, FACC  
Location: Grand Ballroom West, 3rd Floor
7:28 AM - 7:33 AM New Adjunctive Drugs (Plus Statins) To Lower LDL-Cholesterol (LDL-C) In Vascular Patients: Inclisiran, Bempedoic Acid And Ezetimibe: How Do They Work And When And How To Use Them: Level Of LDL-C To Strive For: The CLEAR RCT Show That Bempedoic Acid Really Works
  Presenter(s):Richard Bulbulia, MA, MD, FRCS  
Location: Grand Ballroom West, 3rd Floor
7:34 AM - 7:42 AM Panel Discussion
END OF SESSION 31
previous next